Unpacking Pivotal Data Updates in Metastatic Breast Cancer Management

Massimo Cristofanilli, MD, discusses the next steps with camizestrant in ESR1-mutated HR-positive, HER2-negative advanced breast cancer.

Massimo Cristofanilli, MD, details the implications of serial ESR1 mutation monitoring using ctDNA in HR-positive/HER2-negative advanced breast cancer.

Erica L. Mayer, MD, MPH, discusses the use of imlunestrant in HR+, HER2-negative advanced breast cancer following prior endocrine therapy.

Emergent ESR1-mutant, ER-positive, HER2-negative advanced breast cancer was best treated with camizestrant and continued CDK4/6 inhibition vs SOC therapy.

Patient-reported outcomes revealed that imulunestrant with or without abemaciclib was favored vs SOC in ER-positive, HER2-negative breast cancer.